Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations

NCT06669117 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT06669117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06669117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 22, 2024
Completion date
October 1, 2032
Enrollment
140 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

met alteration, solid tumor